Melanoma live: Making patient-focused therapy decisions

LHRH analogue goserelin helps preserve fertility among women undergoing chemo for hormone receptor-negative breast cancer

KRAS/NRAS and BRAF mutations in study of panitumumab plus FOLFIRI for second-line treatment of mCC

HPV-targeted adoptive T Cell therapy for advanced cervical cancer

PD-1 targeting immunotherapy MK-3475 has high, long-lasting activity against metastatic melanoma

Ipilimumab and nivolumab achieves long-term survival in advanced melanoma

Adjuvant ipilimumab improves recurrence-free survival in high-risk stage III melanoma

HPV-targeted adoptive T Cell therapy may provide a new personalised strategy for advanced cervical cancer

Comment: HPV-targeted adoptive T cell therapy may provide a new strategy for advanced cervical cancer

Comment: Adjuvant ipilimumab in high-risk melanoma

Comment: PD-1 targeting MK-3475 gives long-term responses in melanoma

Comment: Immunotherapy combo increases median survival in advanced melanoma

Success for ipilimumab and nivolumab combo in advanced melanoma

Comment: CALGB/SWOG 80405 study on chemo combos in colorectal

Discontinuing statins near the end of life is safe, improves patient quality of life

Addition of docetaxel to initial hormone therapy substantially improves survival in metastatic, hormone-sensitive prostate cancer

Regorafenib shows early promise in colorectal candidates unable to undergo chemo

Blinatumomab shown to be beneficial in relapsed/refractory B-precursor acute lymphoblastic leukaemia

Inhibition of PD-L1 using drug MPDL3280A for patients with metastatic urothelial bladder cancer

First-line bevacizumab plus chemo and cetuximab plus chemo provide similar survival benefits in metastatic colorectal cancer

Impact of cytotoxics on pregnancy needs to be better understood

T-VEC injections into melanoma lesions show significant response rate

Lower-dose radiation safe for certain lower-risk, HPV-positive head and neck cancers

Phase III SELECT trial shows lenvatinib to be effective in resistant thyroid cancer

ASCO 2014 roundup

Lapatinib not found to be beneficial in head and neck cancer with high risk of recurrence

Adding lapatinib to adjuvant trastuzumab does not improve outcomes in early- stage HER2-positive breast cancer

Genomic sequencing helps identify best candidates for adjuvant chemo in colorectal cancer

Mantle cell lymphoma: A review of data and expert opinion from ASCO 2014

Addition of docetaxel to initial hormone therapy substantially improves survival in metastatic, hormone-sensitive prostate cancer

First-line bevacizumab plus chemo and cetuximab plus chemo provide similar survival benefits in metastatic colorectal cancer

Adding lapatinib to adjuvant trastuzumab does not improve outcomes in early-stage HER2-positive breast cancer

First-line bevacizumab plus chemotherapy and cetuximab plus chemotherapy provide similar survival benefit for patients with metastatic colorectal cancer

Addition of docetaxel to initial hormone therapy substantially improves survival in metastatic, hormone-sensitive prostate cancer

Adjuvant exemestane more effective than tamoxifen when combined with ovarian function suppression in young women with hormone-sensitive, early-stage breast cancer

Adjuvant exemestane is more effective than tamoxifen when combined with ovarian function suppression in young women with hormone-sensitive, early-stage breast cancer

Comment: Advances in breast cancer presented at ASCO 2014

Comment: Advances in lung cancer presented at ASCO 2014

Ramucirumab plus docetaxel extends survival in advanced NSCLC

Targeted drug combo, cediranib plus olaparib, significantly increases progression-free survival in recurrent ovarian cancer

Ibrutinib significantly delays disease progression and extends survival in resistant or relapsed CLL

Lenvatinib yields high response rates and delays progression in radioiodine-resistant, advanced differentiated thyroid cancer

Second-line treatment with ramucirumab plus docetaxel extends survival in advanced NSCLC

Cediranib plus olaparib significantly increases PFS in recurrent ovarian cancer

Ibrutinib significantly delays disease progression and extends survival in resistant or relapsed CLL